Immuneering
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immuneering and other ETFs, options, and stocks.About IMRX
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.
CEOBenjamin J. Zeskind
CEOBenjamin J. Zeskind
Employees66
Employees66
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2008
Founded2008
Employees66
Employees66
IMRX Key Statistics
Market cap431.65M
Market cap431.65M
Price-Earnings ratio-3.75
Price-Earnings ratio-3.75
Dividend yield—
Dividend yield—
Average volume772.32K
Average volume772.32K
High today$6.70
High today$6.70
Low today$6.61
Low today$6.61
Open price$6.76
Open price$6.76
Volume4.23K
Volume4.23K
52 Week high$10.08
52 Week high$10.08
52 Week low$1.10
52 Week low$1.10
Stock Snapshot
The current Immuneering(IMRX) stock price is $6.67, with a market capitalization of 431.65M. The stock trades at a price-to-earnings (P/E) ratio of -3.75.
On 2025-12-05, Immuneering(IMRX) stock moved within a range of $6.61 to $6.70. With shares now at $6.67, the stock is trading +0.9% above its intraday low and -0.4% below the session's peak.
Trading volume for Immuneering(IMRX) stock has reached 4.23K, versus its average volume of 772.32K.
Over the past 52 weeks, Immuneering(IMRX) stock has traded between a high of $10.08 and a low of $1.10.
Over the past 52 weeks, Immuneering(IMRX) stock has traded between a high of $10.08 and a low of $1.10.
Analyst ratings
100%
of 6 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own IMRX. This list is generated using Robinhood data, and it’s not a recommendation.